(Q33762025)

29 July 2017

1 reference

title

FDA approach to the regulation of drugs for diabetes (English)

1 reference

29 July 2017

Fleming A

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

29 July 2017

published in

American Heart Journal

1 reference

29 July 2017

volume

138

1 reference

29 July 2017

issue

5 Pt 1

1 reference

29 July 2017

page(s)

S338-45

1 reference

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970033-5

The Achilles heel of the University Group Diabetes Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970033-5

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970033-5

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970033-5

Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970033-5

The physiologic replacement of insulin. An elusive goal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970033-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970033-5

Epidemiology of adverse drug reactions to phenformin and metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970033-5

Hepatic dysfunction associated with troglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970033-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970033-5

10.1016/S0002-8703(99)70033-5

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference